ArticleNeurobiology of disease2018
Istradefylline reduces memory deficits in aging mice with amyloid pathology.
Open access · greenAbstract read
In one paragraph
Article in Neurobiology of disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 85 citations in OpenAlex.
- Purinergic modulation in Parkinson's disease: the dual role of istradefylline in motor and cognitive outcomes.Purinergic signalling · 2026Review
- Article
- Caffeine attenuates cisplatin induced microglial reactivity and cognitive dysfunction.Frontiers in molecular neuroscience · 2026Article
- Unraveling the anti-neuroinflammatory mechanisms of Cervus cucumis polypeptide injection in Alzheimer's disease: insights from network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation.Frontiers in aging neuroscience · 2026Article
- The emerging role of astrocytes in spatial cognition, action and Alzheimer's disease.Frontiers in cellular neuroscience · 2026Review
- Biphasic actions of the adenosine A2a receptor antagonist istradefylline in mice with obstructive uropathy.Scientific reports · 2025Article
- Upregulation of adenosine AMolecular psychiatry · 2025Article
- The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson's Disease.International journal of molecular sciences · 2025Article
- Impaired Cognitive Flexibility With Preserved Learning in an Amyloid Precursor Protein Knock-In Mouse Model of Amyloidopathy.Genes, brain, and behavior · 2025Article
- Astrocytes Lingering at a Crossroads: Neuroprotection and Neurodegeneration in Neurocognitive Dysfunction.International journal of biological sciences · 2025Review
- The Neuroprotective Role of A2A Adenosine Purinoceptor Modulation as a Strategy Against Glioblastoma.Brain sciences · 2024Review
- Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice.Brain : a journal of neurology · 2024Article
- Hippocampal astrocytes induce sex-dimorphic effects on memory.Cell reports · 2024Article
- Article
- Modification of astrocytic Cx43 hemichannel activity in animal models of AD: modulation by adenosine ACellular and molecular life sciences : CMLS · 2023Article
- Pharmacology of Adenosine Receptors: Recent Advancements.Biomolecules · 2023Review
- Adenosine ABiomolecules · 2023Article
- Chemobrain: An accelerated aging process linking adenosine AInternational review of neurobiology · 2023Review
- Metabolic Regulation of Glia and Their Neuroinflammatory Role in Alzheimer's Disease.Cellular and molecular neurobiology · 2022Review
- Adenosine receptor signalling in Alzheimer's disease.Purinergic signalling · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Anna G OrrGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, CA 94158, USA. Electronic address: ago2002@med.cornell.edu.
Iris LoGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Heike SchumacherGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Kaitlyn HoGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Michael GillGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Weikun GuoGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Daniel H KimGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Anthony KnoxGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Takashi SaitoLaboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako, Saitama 351-0198, Japan.
Takaomi C SaidoLaboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako, Saitama 351-0198, Japan.
Jeffrey SimmsGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Carlee ToddesGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Xin WangGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Gui-Qiu YuGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Lennart MuckeGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, CA 94158, USA. Electronic address: lennart.mucke@gladstone.ucsf.edu.
Gladstone Institutes · USRIKEN Center for Brain Science · JP
Funding
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1MBehavioral CoreP30NS065780 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI MUCKE, LENNART · 2011 to 2015
$4.0MEXTRAMULAR RESEARCH FACILITIES CONSTRUCTIONC06RR018928 · NCRR · J. DAVID GLADSTONE INSTITUTES · PI MAHLEY, ROBERT W. · 2003 to 2003
$2.1MRoles of Astrocytic G Protein-Coupled Signaling in MemoryR00AG048222 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI ORR, ANNA GOLDSHMIDT · 2017 to 2019
$747kRoles of Astrocytic G Protein-Coupled Signaling in MemoryK99AG048222 · NIA · J. DAVID GLADSTONE INSTITUTES · PI ORR, ANNA GOLDSHMIDT · 2014 to 2015
$270kAstrocytic A2A Receptors: Novel Roles and Mechanisms in Alzheimers DiseaseF32AG039220 · NIA · J. DAVID GLADSTONE INSTITUTES · PI ORR, ANNA GOLDSHMIDT · 2011 to 2013
$161kNCRR NIH HHS C06 RR018928NIA NIH HHS F32 AG039220NIA NIH HHS K99 AG048222NIA NIH HHS P50 AG023501NIA NIH HHS R00 AG048222NINDS NIH HHS P30 NS065780
Abstract
Adenosine A
Indexed as
Memory DisordersAdenosine A2 Receptor AntagonistsAgingAlzheimer DiseaseAmyloid beta-PeptidesAnimalsAstrocytesBrainFemaleHumansMaleMiceMice, Inbred C57BLMice, TransgenicPlaque, AmyloidPurinesAdenosine A2 Receptor AntagonistsAdora2a protein, mouseAmyloid beta-PeptidesistradefyllinePurinesReceptor, Adenosine A2AAdenosine receptorsAlzheimer's diseaseAmyloid plaquesAntagonistAstrocytesBehaviorInhibitionIstradefyllineMemoryTherapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.